Metachronous tumour development in the pancreas

Ueno, N.; Kobayashi, N.; Kawamura, H.; Ueda, M.; Endo, I.; Togo, S.; Shimada, H.
December 2006
Gut;Dec2006, Vol. 55 Issue 12, p1703
Academic Journal
A quiz concerning the findings of metachronous tumor development in the pancreas is presented.


Related Articles

  • Evaluation of a Serologic Marker, CA19-9, in the Diagnosis of Pancreatic Cancer. Pleskow, Douglas K.; Berger, Harvey J.; Gyves, John; Allen, Elaine; McLean, Arlene; Podotsky, Daniel K. // Annals of Internal Medicine;5/1/89, Vol. 110 Issue 9, p704 

    Presents a study that determined the utility of the serologic marker CA19-9 in the diagnosis of pancreatic cancer in patients suspected of having a pancreatic disorder. Methodology used in the study; Discussion on the results of the study; Medical care reports.

  • Multimodality staging optimizes resectability in patients... Awad, Samir S.; Colletti, Lisa // American Surgeon;Jul1997, Vol. 63 Issue 7, p634 

    Evaluates the case of consecutive patients with histologically proven pancreatic or ampullary adenocarcinoma related between 1992 and 1996. Patients and methods used in the study; Calculations of sensitivity, specificity and predictive values of resectability and unresectability; Locations of...

  • Photoscanning in Diagnosis of Carcinoma of the Pancreas. Rodriguez-Antunez, Antonio; Filson, Edgar J.; Sellivan, B.H.; Brown, Charles H. // Annals of Internal Medicine;Oct66, Vol. 65 Issue 4, p730 

    Presents a study which examined the use of photoscanning in the diagnosis of carcinoma of the pancreas. Background on photoscanning; Methodology; Results of the study.

  • Two microRNA diagnostic panels may detect pancreatic cancer.  // Hem/Onc Today;3/10/2014, Vol. 15 Issue 5, p19 

    The article discusses research being done on the use of microRNA diagnostic panels in patients with pancreatic cancer, which references a study by N. A. Schultz in a 2014 issue of the "Journal of the American Medical Association."

  • Novel immunoassay detected early stage pancreatic cancer. Sticca, Robert P. // Hem/Onc Today;2/10/2010, Vol. 11 Issue 3, p1 

    The article reports on the findings of a study presented at the 2010 Gastrointestinal Cancers Symposium in Orlando, Florida which claimed that a novel immunoassay that identifies and quantifies blood levels of the PAM4 protein may detect early-stage pancreatic cancer.

  • Coffee consumption and pancreatic cancer: temporal and spatial correlation. Benarde, Melvin A.; Weiss, William // British Medical Journal (Clinical Research Edition);2/6/1982, Vol. 284 Issue 6313, p400 

    Examines the correlation between coffee consumption and pancreatic cancer in the United States. Data on coffee consumption; Differences on the birth cohort cancer curves by race and sex; Utilization of Pearson correlation coefficient to describe the degree of relationship between the two variables.

  • Early screening for pancreatic and ovarian cancer. Simon, Richard; R.M.D. // Cortlandt Forum;9/25/95, Vol. 8 Issue 9, p98 

    Focuses on some of the best early screening procedures to detect cancer of the pancreas and ovary in patients without symptoms. Contrast-enhanced CT scan; Duodenal endoscopic ultrasound.

  • miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1. Iwagami, Y; Eguchi, H; Nagano, H; Akita, H; Hama, N; Wada, H; Kawamoto, K; Kobayashi, S; Tomokuni, A; Tomimaru, Y; Mori, M; Doki, Y // British Journal of Cancer;7/23/2013, Vol. 109 Issue 2, p502 

    Background:Gemcitabine-based chemotherapy is the standard treatment for pancreatic cancer. However, the issue of resistance remains unresolved. The aim of this study was to identify microRNAs (miRNAs) that govern the resistance to gemcitabine in pancreatic cancer.Methods:miRNA microarray...

  • Salivary MicroRNA in Pancreatic Cancer Patients. Humeau, Marine; Vignolle-Vidoni, Alix; Sicard, Flavie; Martins, Frédéric; Bournet, Barbara; Buscail, Louis; Torrisani, Jérôme; Cordelier, Pierre // PLoS ONE;Jun2015, Vol. 10 Issue 6, p1 

    Background: Pancreatic cancer is the fourth leading cause of cancer death in Western countries, with the lowest 1-year survival rate among commonly diagnosed cancers. Reliable biomarkers for pancreatic cancer diagnosis are lacking and are urgently needed to allow for curative surgery. As...

  • ‘One also needs a bit of trust in the doctor … ’: a qualitative interview study with pancreatic cancer patients about their perceptions and views on information and treatment decision-making. Schildmann, J.; Ritter, P.; Salloch, S.; Uhl, W.; Vollmann, J. // Annals of Oncology;Sep2013, Vol. 24 Issue 9, p2444 

    Background Information about diagnosis, treatment options and prognosis has been emphasized as a key to empower cancer patients to make treatment decisions reflecting their values. However, surveys indicate that patients' preferences regarding information and treatment decision-making differ. In...


Read the Article


Sign out of this library

Other Topics